Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-24 @ 11:53 PM
Ignite Modification Date:
2025-12-24 @ 11:53 PM
NCT ID:
NCT05765851
Brief Summary:
This study will evaluate the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors.
Detailed Description:
DS-1103a, a recombinant humanized IgG4 anti-SIRPĪ± antibody designed to block the SIRPĪ±-CD47 interaction, is being developed for the treatment of advanced cancers in combination with other anticancer therapies. This is the first-in-human, dose-escalating clinical study designed to assess the safety and efficacy of DS-1103a combination therapy in patients with advanced solid tumors.
Study:
NCT05765851
Study Brief:
Protocol Section:
NCT05765851